Mylan MYL

  1. All
  2. Commentary
  3. Stock Reports
  4. ETF Reports
  5. Headlines
    1. New Morningstar Analyst Report for Mylan Inc

      Stock Reports

      Tue, 22 Jul 2014

      Compared with its peers, Mylan 's less diversified operations increase ..... volatility in generic drug markets. Mylan faces considerable competition from low ..... Aggressive entry pricing could weaken Mylan 's dominant market position. Mylan

    2. New Morningstar Analyst Report for Abbott Laboratories

      Stock Reports

      Tue, 22 Jul 2014

      line growth more quickly than top-line growth.Abbott's sale of it established pharma business in developed markets to Mylan and its acquisition of CFR and Veropharm have put Abbott's branded generics business in a strong position to benefit from

    3. Why Abbott's Stake In Mylan Will Be Value-Creative

      Headlines

      Mon, 21 Jul 2014

      By Valuentum : Abbott (NYSE: ABT ) has a track record that is unrivaled. The firm is more than 125 years old and remains aligned with favorable long-term healthcare trends in both developed and developing markets. We believe Abbott's nutritionals segment is one of the most attractive businesses in

    4. Mylan wins suit over generic Paxil

      Headlines

      Thu, 17 Jul 2014

      the District of New Jersey grants Mylan 's (NASDAQ: MYL ) motion for a permanent injunction ..... product. The Court also awards Mylan prejudgment interest and permits ..... trial motions. The Court awarded Mylan $106.7M in damages after a favorable

    5. Abbott Labs Delivers Slightly Better-Than-Expected 2Q

      Commentary

      Wed, 16 Jul 2014

      acquisitions of CFR and Veropharm, along with the divestment of Abbott's established pharmaceuticals in the developed markets to Mylan . Importantly, Abbott made progress on profitability as it held manufacturing and operating costs down. We continue to

    6. UPDATE 1-Sanofi held talks with Abbott, Mylan about mature drugs -document

      Headlines

      Wed, 16 Jul 2014

      * Portfolio has sales of 2.1 bln eur, enterprise value 6.3 bln eur

    7. Sanofi held talks with Abbott, Mylan on mature drugs -document

      Headlines

      Wed, 16 Jul 2014

      PARIS, July 16 (Reuters) - Sanofi has held talks with Abbott Laboratories, Mylan and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs,...

    8. Mylan - Much Anticipated Specialty And Branded Generics Deal With Abbott Is Finally A Reality

      Headlines

      Tue, 15 Jul 2014

      By The Value Investor : Mylan (NASDAQ: MYL ) has announced a much anticipated ..... surprise but does mark a big step for Mylan to achieve its long-term earnings ..... at current levels. Deal Highlights Mylan announced that it has reached an agreement

    9. Mylan to buy Abbott generics, cut taxes, in $5.3 billion deal

      Headlines

      Mon, 14 Jul 2014

      (Reuters) - Generic drugmaker Mylan Inc said on Monday it would buy Abbott Laboratories' branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that will bolster its product line and also cut its tax bill.

    10. UPDATE 2- Mylan to buy Abbott generics, cut taxes, in $5.3 bln deal

      Headlines

      Mon, 14 Jul 2014

      (Adds analyst comments, details of deal, company background, stock prices)

    « Prev12345Next »
    Content Partners